Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment
- Author(s):
- Hoes, L.R.; Henegouwen, J.M.V.; Wijngaart, H. van der; Zeverijn, L.J.; Velden, D.L. van der; Haar, J. van de; Roepman, P.; Leng, W.J. de; Jansen, A.M.L.; Werkhoven, E. van; Noort, V. van der; Huitema, A.D.R.; Gort, E.H.; Groot, J.W.B. de; Kerver, E.D.; Groot, D.J. de; Erdkamp, F.; Beerepoot, L.V.; Hendriks, M.P.; Smit, E.F.; Graaf, W.T.A. van der; Herpen, C.M.L. van; Labots, M.; Hoeben, A.; Morreau, H.; Lolkema, M.P.; Cuppen, E.; Gelderblom, H.; Verheul, H.M.W.; Voest, E.E.
- Published
- 2023
- Publication type
- Article / Letter to editor
- Date issued
- 2023-07-01
- Language
- English
- Publisher
- American Association for Cancer Research ({AACR})
- Is part of
- Clinical Cancer Research (2023), Vol. 28, no. 7, p. 1402-1411
- hdl
- 1887/3731098
- doi
- 10.1158/1078-0432.CCR-21-3752
- URL
- https://aacrjournals.org/clincancerres/article/28/7/1402/682217/Patients-with-Rare-Cancers-in-the-Drug-Rediscovery
